company background image
SPPI

Spectrum Pharmaceuticals NasdaqGS:SPPI Stock Report

Last Price

US$0.48

Market Cap

US$87.8m

7D

-24.7%

1Y

-78.6%

Updated

28 Sep, 2022

Data

Company Financials +
SPPI fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

SPPI Stock Overview

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products.

Spectrum Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Spectrum Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.48
52 Week HighUS$2.45
52 Week LowUS$0.41
Beta1.85
1 Month Change-58.10%
3 Month Change-38.76%
1 Year Change-78.58%
3 Year Change-93.88%
5 Year Change-96.75%
Change since IPO-99.65%

Recent News & Updates

Sep 20

Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC

US FDA scientists are concerned about the data Spectrum Pharmaceuticals (NASDAQ:SPPI) has provided to support its drug poziotinib for non-small cell lung cancer ahead of an advisory committee meeting on Thursday. Shares are down 28% in Tuesday morning trading. In a briefing document, the FDA scientists state the data provided shows a low overall response rate (ORR) with minimal duration of response (DOR). ORR was 28% while median DOR was 5.1 months. In addition, they say the safety profile is poor in that at the proposed dosage, 57% of patients experienced dose reductions and 85% of patients had grade 3-4 adverse events. Also, the FDA team faults Spectrum (SPPI) for what it calls inadequate dosage optimization since the company has proposed two different doses for accelerated approval and the planned confirmatory trial. "Confirmation of benefit will be significantly delayed given that confirmatory trial has not begun enrolling patients." Poziotinib is an oral tyrosine kinase inhibitor that inhibits the activity of epidermal growth factor receptor (EGFR [HER1], HER2, and HER4) kinases. Seeking Alpha's Quant Rating views Spectrum (SPPI) as a hold.

Sep 16
Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?

Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Shareholder Returns

SPPIUS BiotechsUS Market
7D-24.7%2.9%-2.0%
1Y-78.6%-24.2%-20.3%

Return vs Industry: SPPI underperformed the US Biotechs industry which returned -27.4% over the past year.

Return vs Market: SPPI underperformed the US Market which returned -22.1% over the past year.

Price Volatility

Is SPPI's price volatile compared to industry and market?
SPPI volatility
SPPI Average Weekly Movement18.7%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: SPPI is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.

Volatility Over Time: SPPI's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1987164Tom Rigahttps://www.sppirx.com

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company’s products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin’s lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002.

Spectrum Pharmaceuticals Fundamentals Summary

How do Spectrum Pharmaceuticals's earnings and revenue compare to its market cap?
SPPI fundamental statistics
Market CapUS$87.77m
Earnings (TTM)-US$117.27m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SPPI income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$117.27m
Earnings-US$117.27m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.64
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did SPPI perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is SPPI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SPPI?

Other financial metrics that can be useful for relative valuation.

SPPI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-0.2x
PEG Ration/a

Price to Book Ratio vs Peers

How does SPPI's PB Ratio compare to its peers?

SPPI PB Ratio vs Peers
The above table shows the PB ratio for SPPI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.8x
CLGN CollPlant Biotechnologies
1.8xn/aUS$72.6m
TSHA Taysha Gene Therapies
2.6x9.7%US$85.5m
MRZM Marizyme
1.9xn/aUS$77.6m
SRZN Surrozen
0.8x-20.9%US$71.3m
SPPI Spectrum Pharmaceuticals
2.6x67.1%US$87.8m

Price-To-Book vs Peers: SPPI is expensive based on its Price-To-Book Ratio (2.6x) compared to the peer average (1.8x).


Price to Earnings Ratio vs Industry

How does SPPI's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: SPPI is expensive based on its Price-To-Book Ratio (2.6x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is SPPI's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SPPI PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate SPPI's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of SPPI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SPPI ($1.06) is trading below our estimate of fair value ($26.23)

Significantly Below Fair Value: SPPI is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Spectrum Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


67.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SPPI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: SPPI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SPPI is expected to become profitable in the next 3 years.

Revenue vs Market: SPPI's revenue (59.5% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: SPPI's revenue (59.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SPPI's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Spectrum Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-12.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SPPI is currently unprofitable.

Growing Profit Margin: SPPI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SPPI is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.

Accelerating Growth: Unable to compare SPPI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SPPI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).


Return on Equity

High ROE: SPPI has a negative Return on Equity (-350.67%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Spectrum Pharmaceuticals's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: SPPI's short term assets ($73.6M) exceed its short term liabilities ($41.0M).

Long Term Liabilities: SPPI's short term assets ($73.6M) exceed its long term liabilities ($4.9M).


Debt to Equity History and Analysis

Debt Level: SPPI is debt free.

Reducing Debt: SPPI has no debt compared to 5 years ago when its debt to equity ratio was 50.1%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SPPI has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: SPPI is forecast to have sufficient cash runway for 11 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies

Dividend

What is Spectrum Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Spectrum Pharmaceuticals Dividend Yield vs Market
How does Spectrum Pharmaceuticals dividend yield compare to the market?
SegmentDividend Yield
Company (Spectrum Pharmaceuticals)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Biotechs)2.7%
Analyst forecast in 3 Years (Spectrum Pharmaceuticals)n/a

Notable Dividend: Unable to evaluate SPPI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SPPI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SPPI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SPPI's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SPPI has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Tom Riga (47 yo)

0.75yr

Tenure

US$2,788,857

Compensation

Mr. Thomas J. Riga, also known as Tom, is President, Chief Executive Officer and Director at Spectrum Pharmaceuticals, Inc. since December 30, 2021. He had been the Chief Operating Officer at Spectrum Phar...


CEO Compensation Analysis

Tom Riga's Compensation vs Spectrum Pharmaceuticals Earnings
How has Tom Riga's remuneration changed compared to Spectrum Pharmaceuticals's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$117m

Mar 31 2022n/an/a

-US$138m

Dec 31 2021US$3mUS$550k

-US$158m

Sep 30 2021n/an/a

-US$169m

Jun 30 2021n/an/a

-US$184m

Mar 31 2021n/an/a

-US$166m

Dec 31 2020US$3mUS$550k

-US$171m

Sep 30 2020n/an/a

-US$162m

Jun 30 2020n/an/a

-US$140m

Mar 31 2020n/an/a

-US$136m

Dec 31 2019US$4mUS$550k

-US$135m

Sep 30 2019n/an/a

-US$148m

Jun 30 2019n/an/a

-US$191m

Mar 31 2019n/an/a

-US$147m

Dec 31 2018US$5mUS$500k

-US$127m

Sep 30 2018n/an/a

-US$102m

Jun 30 2018n/an/a

-US$51m

Mar 31 2018n/an/a

-US$87m

Dec 31 2017US$1mUS$420k

-US$101m

Compensation vs Market: Tom's total compensation ($USD2.79M) is above average for companies of similar size in the US market ($USD784.47K).

Compensation vs Earnings: Tom's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: SPPI's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: SPPI's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

NasdaqGS:SPPI Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
03 Jan 22BuyUS$20,000,000Hanmi Pharm. Co., Ltd.Company12,500,000US$1.60

Ownership Breakdown

What is the ownership structure of SPPI?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders2,465,0061.3%
Public Companies15,332,3318.3%
Hedge Funds17,100,0009.3%
Institutions41,611,57822.6%
General Public107,219,26458.4%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.1%.


Top Shareholders

Top 25 shareholders own 39.76% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.31%
Armistice Capital LLC
17,100,000$8.2m0%0.18%
8.35%
Hanmi Pharm. Co., Ltd.
15,332,331$7.3m0%no data
4.81%
The Vanguard Group, Inc.
8,828,676$4.2m10.86%no data
4.38%
D. E. Shaw & Co., L.P.
8,051,858$3.8m2.63%0.01%
4.29%
BlackRock, Inc.
7,878,203$3.8m-50.1%no data
1.46%
Millennium Management LLC
2,681,100$1.3m253.83%no data
0.96%
Morgan Stanley, Investment Banking and Brokerage Investments
1,767,179$844.2k7.38%no data
0.94%
Geode Capital Management, LLC
1,735,725$829.2k-36.36%no data
0.65%
Renaissance Technologies LLC
1,191,049$569.0k-15.17%no data
0.45%
Thomas Riga
822,439$392.9k41.08%no data
0.43%
Alethea Capital Management, LLC
787,973$376.4k-33.06%0.38%
0.41%
Citadel Advisors LLC
755,128$360.7k5327.5%no data
0.41%
Ergoteles LLC
744,275$355.5k148.92%0.01%
0.39%
State Street Global Advisors, Inc.
721,769$344.8k-78.38%no data
0.33%
Sargent Investment Group, LLC
614,600$293.6k48.24%0.09%
0.33%
CM Management, LLC
600,000$286.6k0%0.28%
0.3%
Fisher Asset Management, LLC
545,198$260.4k0%no data
0.25%
Dimensional Fund Advisors LP
459,885$219.7k-13.22%no data
0.24%
Wells Fargo & Company, Securities and Brokerage Investments
434,401$207.5k-1.81%no data
0.22%
Joseph Turgeon
396,525$189.4k-30.01%no data
0.21%
U.S. Bancorp Asset Management, Inc.
389,142$185.9k0%no data
0.18%
Kurt Gustafson
329,099$157.2k0%no data
0.18%
Northern Trust Global Investments
327,751$156.6k-77.74%no data
0.17%
Susquehanna International Group, LLP, Asset Management Arm
305,393$145.9k15.61%no data
0.14%
Keith McGahan
251,190$120.0k0%no data

Company Information

Spectrum Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Spectrum Pharmaceuticals, Inc.
  • Ticker: SPPI
  • Exchange: NasdaqGS
  • Founded: 1987
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$87.767m
  • Shares outstanding: 183.73m
  • Website: https://www.sppirx.com

Number of Employees


Location

  • Spectrum Pharmaceuticals, Inc.
  • Pilot House – Lewis Wharf
  • 6th Floor
  • Boston
  • Massachusetts
  • 2110
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SPPINasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDSep 1996
NTRDB (Deutsche Boerse AG)YesCommon SharesDEEURSep 1996

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/28 00:00
End of Day Share Price2022/09/28 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.